Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2021-04-15 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于公司参与投资基金的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of the company's participation in an investment fund. It details the investment amount, the fund's registration, capital contributions, and risk warnings. There is no financial statement or detailed financial analysis presented. The document is a progress update on a capital investment activity, not a full financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it relates to the company's financing activities and investment in a fund.
2021-04-15 Chinese
昆药集团2021年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第一季度报告' which translates to '2021 First Quarter Report'. It contains detailed financial data including consolidated balance sheets, profit and loss statements, and notes on company operations and financial performance for the first quarter of 2021. The report includes unaudited financial statements, management discussion on business segments, financial metrics, shareholder information, and important events during the quarter. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive quarterly financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-15 Chinese
昆药集团独立董事关于公司会计政策变更的独立意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding a change in the company's accounting policies. It references regulatory guidelines and confirms the appropriateness and compliance of the accounting policy change. The document is short (364 characters) and serves as an independent opinion rather than a full audit report or financial statement. It does not contain detailed financial data or audit results but is a formal opinion related to governance and compliance. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related announcement without substantive financial data or audit report content.
2021-04-15 Chinese
昆药集团2021年第一季度报告_正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第一季度报告' which translates to '2021 First Quarter Report'. It contains detailed financial data including total assets, net profit, cash flow, and other financial metrics for the quarter. It also includes shareholder information and notes on important matters such as stock incentive plans, financing activities, and legal proceedings. The document is comprehensive and contains actual financial statements and analysis for a period shorter than a full fiscal year (a quarter). It is not merely an announcement or a certification but a full quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-15 Chinese
昆药集团关于公司会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in the company's accounting policies, specifically the adoption of a new lease accounting standard effective from January 1, 2021. It includes details about the policy change, its impact, and opinions from independent directors and the supervisory board. The document is relatively short (1534 characters) and does not contain actual financial statements or detailed financial data. It is an announcement of a policy change rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2021-04-15 Chinese
昆药集团九届二十九次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board of Kunming Pharmaceutical Group regarding the approval of the company's accounting policy changes and the 2021 first quarter report. It includes the supervisory board's written review and approval of the 2021 Q1 report, confirming compliance with laws and regulations and the accuracy of the report. The document itself does not contain the full financial statements or detailed financial data of the quarterly report but rather the supervisory board's approval and opinion on it. The document length is short (895 characters), and it serves as an official announcement of the supervisory board's resolution and approval rather than the full interim/quarterly report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal announcement related to regulatory compliance and supervisory board approval, not the full quarterly report (IR).
2021-04-15 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.